
Prevention & Lipids
Blood pressure targets and treatment strategies
Synthesized from 134 evidence-backed clinical questions linked to this topic — 36 supporting the intervention, 42 against the intervention, 10 still contested.
No clear lean — the placed evidence is contested
36
Favor benefit
27% of all
42
Favor harm
31% of all
46 more (34%) still untested — not placed on the axis.
Low certainty on 58% of questions
Does antihypertensive drugs vs placebo improve outcomes in Frailty?
Low Certainty+ Favors benefitantihypertensive drugs vs placebo
7 studies (8,985,214 patients) provide low-certainty evidence for benefit of antihypertensive drugs for the outcome in Frailty.
Does antihypertensive vs placebo improve outcomes in Stroke?
Low Certainty− Favors harmantihypertensive vs placebo
8 studies (5,289,215 patients) provide low-certainty evidence against benefit of antihypertensive for the outcome in Stroke.
Does angiotensin receptor blockers vs placebo improve outcomes in Hypertensive disease?
Low Certainty− Favors harmangiotensin receptor blockers vs placebo
26 studies (3,889,575 patients) provide low-certainty evidence against benefit of angiotensin receptor blockers for the outcome in Hypertensive disease.
Does statin vs placebo improve outcomes in Hypertensive disease?
Low Certainty− Favors harmstatin vs placebo
13 studies (1,558,581 patients) provide low-certainty evidence against benefit of statin for the outcome in Hypertensive disease.
Does metoprolol vs propranolol improve outcomes in Hypertensive disease?
Low Certainty− Favors harmmetoprolol vs propranolol
6 studies (1,051,130 patients) provide low-certainty evidence against benefit of metoprolol for the outcome in Hypertensive disease.
Does diuretics vs placebo improve outcomes in Hypertensive disease?
Low Certainty− Favors harmdiuretics vs placebo
26 studies (903,774 patients) provide low-certainty evidence against benefit of diuretics for the outcome in Hypertensive disease.
Does antihypertensives vs placebo improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsantihypertensives vs placebo · Cardiac Output
452 studies (266,807,266 patients) provide insufficient evidence with mixed findings regarding antihypertensives for Cardiac Output in Hypertensive disease.
Does angiotensin converting enzyme inhibitor vs angiotensin receptor blocker improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsangiotensin converting enzyme inhibitor vs angiotensin receptor blocker
10 studies (7,152,153 patients) provide insufficient evidence with mixed findings regarding angiotensin converting enzyme inhibitor for the outcome in Hypertensive disease.
Does amlodipine vs chlorthalidone improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsamlodipine vs chlorthalidone
8 studies (136,774 patients) provide insufficient evidence with mixed findings regarding amlodipine for the outcome in Hypertensive disease.
Does antihypertensive drugs vs diuretic improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsantihypertensive drugs vs diuretic
6 studies (7,903,740 patients) provide insufficient evidence with mixed findings regarding antihypertensive drugs for the outcome in Hypertensive disease.
Emerging evidence with 100 primary claims
Hemodynamic Effect of Long‐term Treatment with Pindolol in Essential Hypertension with Special Reference to the Resistance and Capacitance Vessels of the Forearm
Acta Medica Scandinavica — Atterhög J — Jan 1977
Vasodilator Capacity of Forearm Vessels in Hypertension
Clinical and Experimental Hypertension — Ogilvie R — Jan 1982
Early Structural Changes in Precapillary Vessels in Hypertension and Their Relationship to Functional Changes
Journal of Cardiovascular Pharmacology — Daniel E — Jan 1984
The relationship between altered blood vessel structure, hypertension, and the sympathetic nervous system
Canadian Journal of Physiology and Pharmacology — Scott T — Apr 1985
Mobile health application usage and quality of care at a hypertension clinic: an observational cohort study
Journal of Hypertension — Agnihothri S — Jun 2021
Development and validation of a risk predictive model in young patients with hypertension
Medicine — Zhao X — Oct 2025
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients from a well‐defined region
European Journal Of Haematology — Andersson M — Aug 2023
Renal function after new treatment with renin-angiotensin system blockers
BMJ — Valente M — Mar 2017
Left Ventricular Mass and Incident Chronic Kidney Disease
Hypertension — Jan 2020
Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor?
Nephrology Dialysis Transplantation — Rabelink T — Dec 2003
Aortic dissection: Prompt diagnosis and emergency treatment are critical
Cleveland Clinic Journal of Medicine — Braverman A — Oct 2011
Clustering of Risk Factors Increases the Incidence of Echolucent Carotid Plaque in Stroke Patients
Cerebrovascular Diseases — Yamashiro K — Jan 2006
The evidence sections above show what the literature supports; this is what the field is still arguing about. Open a debate for the camps, the named voices, and the vote.
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Hypertension management (also known as HTN, high blood pressure, BP management). Blood pressure targets and treatment strategies
As of 2026-09-04, the scientific consensus on Hypertension management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hypertension-management.
Deterministic synthesis from Synapse's enriched corpus — 57 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Hypertension management paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Hypertension management papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers